APR 14·Stock TitanMed
Schizophrenia study tracks symptom gains for 56 weeks on LYBALVI
Alkermes plc announced the publication of a 56-week post hoc analysis in The Journal of Clinical Psychiatry, revealing sustained reduction in negative symptoms of schizophrenia with LYBALVI. The study, derived from patients who completed ENLIGHTEN-1 and its 52-week extension, showed improvements in various subscale scores, further validating LYBALVI's utility for this challenging condition. This analysis highlights the drug's role in addressing hard-to-treat negative symptoms while also mitigating olanzapine-associated weight gain.